# advanced or metastatic Merkel cell carcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/advanced-or-metastatic-merkel-cell-carcinoma

> 2 upcoming FDA catalysts in advanced or metastatic Merkel cell carcinoma: ifx-hu2.0 (HURA) on Mar to Jun 2027 (topline data readout); ifx-hu2.0 (HURA) on March 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2025 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | HURA | advanced or metastatic Merkel cell carcinoma | completed | "In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor na&iuml;ve utilizing the FDA's accelerated approval pathway." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/d73851dex991.htm)) |
| Mar to Jun 2027 | [Ifx-hu2.0 topline data readout](https://sec-api.dev/pdufa/ifx-hu2-0) | HURA | Advanced Or Metastatic Merkel Cell Carcinoma | scheduled | "NCT06947928 (Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor TuHURA Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947928)) |
| March 2027 | [Ifx-hu2.0 primary completion](https://sec-api.dev/pdufa/ifx-hu2-0) | HURA | Advanced Or Metastatic Merkel Cell Carcinoma | scheduled | "NCT06947928 (Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor TuHURA Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947928)) |

## Drugs

- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Ifx-hu2.0](https://sec-api.dev/pdufa/ifx-hu2-0) (HURA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/advanced-or-metastatic-merkel-cell-carcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "advanced or metastatic Merkel cell carcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/advanced-or-metastatic-merkel-cell-carcinoma

```bibtex
@misc{secapidev_indications_advanced_or_metastatic_merkel_cell_carcinoma_20261116,
  title        = {advanced or metastatic Merkel cell carcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/advanced-or-metastatic-merkel-cell-carcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_advanced_or_metastatic_merkel_cell_carcinoma_20261116","title":"advanced or metastatic Merkel cell carcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/advanced-or-metastatic-merkel-cell-carcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
